ORIC Pharmaceuticals Gains Buy Rating, Stock Rises
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Coverage Resumption and Buy Rating: Stifel has resumed coverage of ORIC Pharmaceuticals with a Buy recommendation, citing a compelling risk-reward setup ahead of an upcoming late-stage trial, which is expected to drive stock price appreciation.
- Late-Stage Trial Plans: ORIC plans to initiate a late-stage trial for its lead asset rinzimetostat in June/July, targeting the inhibition of the PRC2 protein in metastatic castration-resistant prostate cancer, which is anticipated to yield significant clinical data for the company.
- Analyst Optimism: Analyst Laura Prendergast highlighted that a late-stage trial readout from Pfizer's PRC2 inhibitor mevrometostat is expected in mid-H2 2026, which could serve as the next major catalyst for ORIC, further boosting market confidence.
- Financial Health and Market Opportunity: ORIC's high short interest and cash reserves, which represent about 50% of its market capitalization, provide strong financial backing, leading analysts to believe in the potential success of rinzimetostat in mCRPC.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 7.820
Low
15.00
Averages
19.60
High
25.00
Current: 7.820
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ORIC Pharmaceuticals Gains Buy Rating, Stock Rises
- Coverage Resumption and Buy Rating: Stifel has resumed coverage of ORIC Pharmaceuticals with a Buy recommendation, citing a compelling risk-reward setup ahead of an upcoming late-stage trial, which is expected to drive stock price appreciation.
- Late-Stage Trial Plans: ORIC plans to initiate a late-stage trial for its lead asset rinzimetostat in June/July, targeting the inhibition of the PRC2 protein in metastatic castration-resistant prostate cancer, which is anticipated to yield significant clinical data for the company.
- Analyst Optimism: Analyst Laura Prendergast highlighted that a late-stage trial readout from Pfizer's PRC2 inhibitor mevrometostat is expected in mid-H2 2026, which could serve as the next major catalyst for ORIC, further boosting market confidence.
- Financial Health and Market Opportunity: ORIC's high short interest and cash reserves, which represent about 50% of its market capitalization, provide strong financial backing, leading analysts to believe in the potential success of rinzimetostat in mCRPC.
See More
ORIC Pharmaceuticals Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 1, 2026, ORIC Pharmaceuticals granted 34,800 non-qualified stock options and 5,900 restricted stock units to two new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the clinical stage.
- Grant Plan Details: Under the 2022 Inducement Equity Incentive Plan, the stock options have an exercise price equal to the closing price on the Grant Date, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring long-term employee commitment.
- Restricted Stock Units Arrangement: One-third of the restricted stock units will vest on each of the first three anniversaries of the Grant Date, which not only incentivizes long-term employee commitment but also enhances team stability and execution capabilities.
- Compliance and Approval: The grants were approved by ORIC's Compensation Committee, in accordance with Nasdaq Rule 5635(c)(4), ensuring compliance and transparency in talent attraction, which further boosts investor confidence.
See More
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Stock Price Plunge: Following ORIC's announcement that its prostate cancer treatment rinzimetostat (ORIC-944) is not as effective as expected, the stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting market disappointment in its product prospects.
- Potential Legal Action: Investors are advised to contact Pomerantz LLP regarding the possibility of joining a class action lawsuit, which could result in significant financial liabilities for the company, further impacting its financial health.
- Reputation Damage: The ongoing investigation and stock price decline have severely damaged ORIC's market reputation, potentially affecting its future financing and business development plans.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which negatively impacted market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating investor concerns regarding the company's future prospects.
- Potential Legal Action: Pomerantz LLP advises investors to contact their attorneys to join a possible class action lawsuit, highlighting the legal risks the company faces, which may affect future shareholder trust and market performance.
See More
Wall Street's Latest Upgrade Calls Overview
- RXO Upgrade: Stifel upgraded RXO from hold to buy, citing a favorable market setup emerging into the latter half of 2026, particularly at the intersection of improving brokerage fundamentals and unique idiosyncratic levers, indicating potential growth opportunities.
- Cisco Rating Boost: HSBC upgraded Cisco to buy from hold following the company's recent earnings report, raising the price target from $77 to $137, reflecting strong momentum in AI infrastructure and improved earnings visibility.
- Arista Networks Upgrade: Raymond James upgraded Arista Networks from market perform to outperform, anticipating improved sales growth in 2027 and beyond, particularly as the company expands into AI backend and campus applications, enhancing its market share.
- Dell Reiteration: Morgan Stanley reiterated its overweight rating on Dell, raising the price target from $205 to $280, expecting the company to raise its FY27 earnings guidance again, although supply visibility still needs to catch up with the high demand outlook for AI servers.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- Stock Price Plunge: Following the March 31, 2026, announcement regarding the effectiveness of ORIC's prostate cancer treatment rinzimetostat (ORIC-944), which fell short of expectations, the stock price plummeted by 41% to close at $7.48 per share, reflecting market disappointment in the product's competitiveness.
- Potential Legal Action: The investigation may lead to a class action lawsuit, with investors encouraged to contact Pomerantz LLP, indicating a significant loss of confidence in the company's future performance, which could impact its financing capabilities and market reputation.
- Historical Context: Pomerantz LLP is a prominent firm in the securities class action field, established over 85 years ago, having recovered millions in damages for victims, demonstrating its strong commitment to protecting investor rights.
See More
ORIC Pharmaceuticals Gains Buy Rating, Stock Rises
- Coverage Resumption and Buy Rating: Stifel has resumed coverage of ORIC Pharmaceuticals with a Buy recommendation, citing a compelling risk-reward setup ahead of an upcoming late-stage trial, which is expected to drive stock price appreciation.
- Late-Stage Trial Plans: ORIC plans to initiate a late-stage trial for its lead asset rinzimetostat in June/July, targeting the inhibition of the PRC2 protein in metastatic castration-resistant prostate cancer, which is anticipated to yield significant clinical data for the company.
- Analyst Optimism: Analyst Laura Prendergast highlighted that a late-stage trial readout from Pfizer's PRC2 inhibitor mevrometostat is expected in mid-H2 2026, which could serve as the next major catalyst for ORIC, further boosting market confidence.
- Financial Health and Market Opportunity: ORIC's high short interest and cash reserves, which represent about 50% of its market capitalization, provide strong financial backing, leading analysts to believe in the potential success of rinzimetostat in mCRPC.
See More
ORIC Pharmaceuticals Grants Stock Options and RSUs to New Employees
- Stock Option Grant: On June 1, 2026, ORIC Pharmaceuticals granted 34,800 non-qualified stock options and 5,900 restricted stock units to two new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the clinical stage.
- Grant Plan Details: Under the 2022 Inducement Equity Incentive Plan, the stock options have an exercise price equal to the closing price on the Grant Date, with 25% vesting on the one-year anniversary and the remainder vesting monthly, ensuring long-term employee commitment.
- Restricted Stock Units Arrangement: One-third of the restricted stock units will vest on each of the first three anniversaries of the Grant Date, which not only incentivizes long-term employee commitment but also enhances team stability and execution capabilities.
- Compliance and Approval: The grants were approved by ORIC's Compensation Committee, in accordance with Nasdaq Rule 5635(c)(4), ensuring compliance and transparency in talent attraction, which further boosts investor confidence.
See More
Pomerantz LLP Investigates ORIC Pharmaceuticals for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ORIC Pharmaceuticals and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Stock Price Plunge: Following ORIC's announcement that its prostate cancer treatment rinzimetostat (ORIC-944) is not as effective as expected, the stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, reflecting market disappointment in its product prospects.
- Potential Legal Action: Investors are advised to contact Pomerantz LLP regarding the possibility of joining a class action lawsuit, which could result in significant financial liabilities for the company, further impacting its financial health.
- Reputation Damage: The ongoing investigation and stock price decline have severely damaged ORIC's market reputation, potentially affecting its future financing and business development plans.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of ORIC Pharmaceuticals investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- Drug Efficacy Below Expectations: On March 31, 2026, ORIC announced that its prostate cancer treatment rinzimetostat (ORIC-944) is only as effective as a competitor, failing to meet expectations of being the best in its class, which negatively impacted market confidence.
- Significant Stock Price Drop: Following this news, ORIC's stock price fell by $5.20, or 41%, closing at $7.48 per share on April 1, 2026, indicating investor concerns regarding the company's future prospects.
- Potential Legal Action: Pomerantz LLP advises investors to contact their attorneys to join a possible class action lawsuit, highlighting the legal risks the company faces, which may affect future shareholder trust and market performance.
See More
Wall Street's Latest Upgrade Calls Overview
- RXO Upgrade: Stifel upgraded RXO from hold to buy, citing a favorable market setup emerging into the latter half of 2026, particularly at the intersection of improving brokerage fundamentals and unique idiosyncratic levers, indicating potential growth opportunities.
- Cisco Rating Boost: HSBC upgraded Cisco to buy from hold following the company's recent earnings report, raising the price target from $77 to $137, reflecting strong momentum in AI infrastructure and improved earnings visibility.
- Arista Networks Upgrade: Raymond James upgraded Arista Networks from market perform to outperform, anticipating improved sales growth in 2027 and beyond, particularly as the company expands into AI backend and campus applications, enhancing its market share.
- Dell Reiteration: Morgan Stanley reiterated its overweight rating on Dell, raising the price target from $205 to $280, expecting the company to raise its FY27 earnings guidance again, although supply visibility still needs to catch up with the high demand outlook for AI servers.
See More
Pomerantz LLP Investigates Securities Fraud Claims Against ORIC Pharmaceuticals
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- Stock Price Plunge: Following the March 31, 2026, announcement regarding the effectiveness of ORIC's prostate cancer treatment rinzimetostat (ORIC-944), which fell short of expectations, the stock price plummeted by 41% to close at $7.48 per share, reflecting market disappointment in the product's competitiveness.
- Potential Legal Action: The investigation may lead to a class action lawsuit, with investors encouraged to contact Pomerantz LLP, indicating a significant loss of confidence in the company's future performance, which could impact its financing capabilities and market reputation.
- Historical Context: Pomerantz LLP is a prominent firm in the securities class action field, established over 85 years ago, having recovered millions in damages for victims, demonstrating its strong commitment to protecting investor rights.
See More
